These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23400746)

  • 61. Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain.
    Kim CK; Yang XL; Kim YJ; Choi IY; Jeong HG; Park HK; Kim D; Kim TJ; Jang H; Ko SB; Yoon BW
    Biomed Res Int; 2015; 2015():295925. PubMed ID: 26448932
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
    Ishiguro N; Maeda K; Kishimoto W; Saito A; Harada A; Ebner T; Roth W; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1109-15. PubMed ID: 16611857
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bioequivalence study of two oral formulations of irbesartan 300 mg in healthy volunteers.
    Cánovas M; Cabré F; Polonio F
    Drug Res (Stuttg); 2014 Jan; 64(1):53-6. PubMed ID: 24048950
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
    He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
    Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.
    Ziesenitz VC; König SK; Mahlke N; Jantos R; Skopp G; Weiss J; Haefeli WE; Mikus G
    Basic Clin Pharmacol Toxicol; 2013 Jul; 113(1):43-8. PubMed ID: 23480028
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
    Oswald S; König J; Lütjohann D; Giessmann T; Kroemer HK; Rimmbach C; Rosskopf D; Fromm MF; Siegmund W
    Pharmacogenet Genomics; 2008 Jul; 18(7):559-68. PubMed ID: 18551036
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3.
    Jeong ES; Kim YW; Kim HJ; Shin HJ; Shin JG; Kim KH; Chi YH; Paik SH; Kim DH
    Xenobiotica; 2015 Jan; 45(1):10-8. PubMed ID: 25034008
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
    Izumi S; Nozaki Y; Maeda K; Komori T; Takenaka O; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2015 Feb; 43(2):235-47. PubMed ID: 25414411
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
    Zhi J; Zhai S; Georgy A; Liang Z; Boldrin M
    J Clin Pharmacol; 2016 May; 56(5):548-54. PubMed ID: 26272330
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multivariate Assessment for Bioequivalence Based on the Correlation of Random Effect.
    An H; Shin D
    Drug Des Devel Ther; 2021; 15():3675-3683. PubMed ID: 34465979
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.
    Bruderer S; Aänismaa P; Homery MC; Häusler S; Landskroner K; Sidharta PN; Treiber A; Dingemanse J
    AAPS J; 2012 Mar; 14(1):68-78. PubMed ID: 22189899
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
    Juif PE; Voors-Pette C; Ufer M; Dogterom P; Dingemanse J
    Clin Transl Sci; 2019 Sep; 12(5):440-444. PubMed ID: 31004470
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study.
    Imai H; Oikawa I; Koyama T; Matsuki S
    Br J Clin Pharmacol; 2024 Jun; 90(6):1395-1407. PubMed ID: 38408756
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure.
    Quan H; Oh GC; Seok SH; Lee HY
    Korean J Intern Med; 2020 Nov; 35(6):1400-1410. PubMed ID: 32164398
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.
    Mukker JK; Dukes G; Tolkoff M; Wang L; Almansa C; Huh SY; Nishihara M; Ramsden D; Chen C
    Clin Transl Sci; 2022 Jun; 15(6):1532-1543. PubMed ID: 35460165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Characterization of fimasartan metabolites in human liver microsomes and human plasma.
    Lee JY; Choi YJ; Oh SJ; Chi YH; Paik SH; Lee KH; Jung JK; Ryu CS; Kim KB; Kim DH; Yoon YR; Kim SK
    Xenobiotica; 2016; 46(1):40-51. PubMed ID: 26068523
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells.
    Jang YN; Lee YJ; Han YM; Kim HM; Seo HS; Jeong JH; Park SY; Jung TW
    Yonsei Med J; 2022 Jun; 63(6):530-538. PubMed ID: 35619576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.